Effectiveness of Systemic Corticosteroids Therapy for Nonsevere Patients With COVID-19: A Multicenter, Retrospective, Longitudinal Cohort Study

Chen, Zhenyuan; Yin, Xiaoxv; Tan, Xiaohong; Wang, Jing; Jiang, Nan; Tian, Mi; Li, Hui; Lu, Zuxun; Xiong, Nian; Gong, Yanhong

doi:10.1016/j.jval.2021.12.013

Cited by 8 publications

(2 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hasil dari penelitian ini menunjukkan pada pasien COVID-19 dengan kebutuhan oksigen tambahan atau ventilator mekanik yang mendapatkan terapi deksametason dapat meningkatkan kebutuhan penggunaan terapi untuk hiperglikemia khususnya penggunaan terapi insulin yang meningkat melebihi dosis standar. (Chen et al, 2022) suatu multicenter kohort retrospektif menilai efektivitas dari terapi kortikosteroid sistemik pada pasien non-severe COVID-19. Penelitian ini mengamati terkait penggunaan kortikosteroid sistemik yang meliputi metilprednisolon, deksametason, prednison, prednisolon, hidrokortison, dengan dosis setara dengan 200 mg hidrokortison.…”

Section: Hasil Dan Pembahasanunclassified

Narrative Review: Terapi Kortikosteroid Pada Pasien COVID-19 dengan Komorbiditas Diabetes Melitus

Dewi,

Andayani,

Trisnawati

2023

jharma

View full text Add to dashboard Cite

COVID-19 is a respiratory disease caused by SARS-CoV-2, a corona virus that was discovered at the end of 2019. Diabetes mellitus (DM) is the second highest comorbidities in Indonesia of COVID-19 patients. One of the treatments for COVID-19 patients is corticosteroids. Commonly used corticosteroids are dexamethasone, methylprednisolone, and hydrocortisone. This study aims to determine the effect of corticosteroid therapy in COVID-19 patients with DM comorbidities so that it can be a source of information and a reference in the management of therapy in patients. This research is a narrative review using literature from the science databases Cochrane, PubMed and Science Direct. Literature search used the keywords COVID-19, diabetes, and corticosteroids. The results of the literature screening obtained 16 study articles that met the inclusion criteria. The conclusion of this narrative review study is that the recommended corticosteroid therapy for COVID-19 patients is dexamethasone. Administering corticosteroids to COVID-19 patients with comorbid DM can increase the incidence of hyperglycemia, especially at high doses and in the long term, thereby worsening the patient's prognosis, causing new onset diabetes, and increasing the need for insulin doses.

show abstract

Section: Hasil Dan Pembahasanunclassified

Narrative Review: Terapi Kortikosteroid Pada Pasien COVID-19 dengan Komorbiditas Diabetes Melitus

Dewi,

Andayani,

Trisnawati

2023

jharma

View full text Add to dashboard Cite

show abstract

“…A more recently published controlled observational study also found systemic corticosteroids to be associated with a higher risk of developing severe COVID-19 (hazard ratio (HR): 1.81 (1.47-2.21)) and a longer hospitalisation. It also reported a higher all-cause mortality rate (HR 2.92 (1.39-6.15)) in non-severe patients who used corticosteroids (29.8% of 1726) [11].…”

mentioning

confidence: 92%

A potential harmful effect of dexamethasone in non-severe COVID-19: results from the COPPER-pilot study

et al. 2022

View full text Add to dashboard Cite

show abstract

Comparative Effectiveness of Dexamethasone in Hospitalized COVID-19 Patients in the United States

et al. 2022

View full text Add to dashboard Cite

Effectiveness of Systemic Corticosteroids Therapy for Nonsevere Patients With COVID-19: A Multicenter, Retrospective, Longitudinal Cohort Study

Cited by 8 publications

References 50 publications

Narrative Review: Terapi Kortikosteroid Pada Pasien COVID-19 dengan Komorbiditas Diabetes Melitus

Narrative Review: Terapi Kortikosteroid Pada Pasien COVID-19 dengan Komorbiditas Diabetes Melitus

A potential harmful effect of dexamethasone in non-severe COVID-19: results from the COPPER-pilot study

Comparative Effectiveness of Dexamethasone in Hospitalized COVID-19 Patients in the United States

Contact Info

Product

Resources

About